Report ID : 10059482 |
Published Date : 21 Mar 2025 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Overactive Bladder Treatment Market Scope Report
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~5% |
|
Base Year Market Size (2022) |
~ USD 4.0 Billion |
|
Forecast Year Market Size (2033) |
~ USD 9.0 Billion |
Global Overactive Bladder Treatment Market Highlights Over 2023 - 2033
The global overactive bladder treatment market is estimated to garner a revenue of USD 9.0 Billion by the end of 2033 by growing at a CAGR of ~5% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of USD 4.0 Billion in the year 2022. The growth of the market can be attributed to the increasing number of people dealing with overactive bladder. Nearly 7 Million people in the United Kingdom have urinary incontinence in the year 2019.
GET A SAMPLE COPY OF THIS REPORT
Overactive bladder (OAB) refers to a condition in which a person's need to urinate is so frequent that it negatively affects their life. There are many causes that account for overactive bladder, such as infection, nerve damage, abdominal trauma, and others. The drugs that help for the treatment of the patients includes darifenacin, anticholinergics, oxybutynin, solifenacin, and others. Moreover, there has been continuous efforts by the pharmaceutical industry to find out new innovative treatments for the overactive bladder. Therefore, the growth of pharmaceutical industry is anticipated to increase the growth of the global overactive bladder treatment market. As per the India Brand Equity Foundation, foreign direct investment in drugs and pharmaceuticals accounted for USD 19.41 Billion in between April 2000 -March 2022.
Global Overactive Bladder Treatment Market: Growth Drivers and Challenges
Growth Drivers
-
Surging Kidney Related Disorders– The urge to urinate can be increased owing to kidney problems such as when the kidney filters are damaged. Hence, it is expected to boost the growth of the global overactive bladder treatment market. As per the report stated by the Centers, more than 37 Million people accounted to have chronic kidney diseases.
-
Growing Geriatric Population – According to the data reported by the World Health Organization, 1 in 6 people around the world will be aged 60 years or above by the end of 2031.
-
Rising Prevalence of Chronic Diseases– As per the World Health Organization, nearly 422 Million people across the globe have diabetes.
-
Rising Research & Development Expenditure – According to the World Bank, research and development expenditure has increased from 2.05 per cent of GDP in 2000 to 2.63 per cent of GDP in 2020.
Challenges
-
Lack of Awareness Related to Overactive Bladder
-
Scarcity of Skilled Medical Professionals
-
High Cost for the Treatment
The global overactive bladder treatment market is segmented and analyzed for demand and supply by disease type into neurogenic, and idiopathic bladder overactivity. Out of these, the neurogenic bladder overactivity segment is anticipated to hold the largest share over the forecast period owing to the high prevalence of neurogenic bladder disorders across the globe. For instance, neurogenic bladders are found in nearly 40 t0 90 per cent of patients with multiple sclerosis and 15 per cent of all stroke patients in the United States.
Global Overactive Bladder Treatment Market Regional Synopsis
Regionally, the global overactive bladder treatment market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in the North America region is projected to hold the largest market share by the end of 2033 on the back of an increasing incidence of patients dealing with overactive bladder, and rising reimbursement policies for the treatment. As per the Urology Care Foundation, nearly 40 per cent women and 30 per cent men live with overactive bladder symptoms in the United States.
Market Segmentation
Our in-depth analysis of the global overactive bladder treatment market includes the following segments:
|
By Disease Type |
|
|
By Drug Type |
|
Key Companies Dominating the Global Overactive Bladder Treatment Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global overactive bladder treatment market that are included in our report are Bio-Rad Laboratories, Inc., Hologic, Inc., F.Hoffmann-La Roche Ltd, AbbVie Inc, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Thermo Fisher Scientific, Intas Pharmaceuticals Ltd, Viatris Inc., Hisamitsu Pharmaceutical Co, Inc., and others.
Global Overactive Bladder Treatment Market: Latest Developments
-
April, 2019: Teva Pharmaceutical Industries Ltd announced the launch of generic version of VESIcare tablets for the treatment of overactive bladder in the United States.
-
November, 2018: Hisamitsu Pharmaceutical Co, Inc., announced the acquisition of an approval of manufacturing and marketing permit for OABLOK PATCH in Taiwan.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
